{"id":260717,"date":"2023-11-08T10:11:11","date_gmt":"2023-11-08T15:11:11","guid":{"rendered":"https:\/\/platohealth.ai\/new-postpartum-depression-drug-zurzuvae-zuranolone-comes-with-hefty-price-tag-drugs-com-mednews\/"},"modified":"2023-11-08T14:26:02","modified_gmt":"2023-11-08T19:26:02","slug":"new-postpartum-depression-drug-zurzuvae-zuranolone-comes-with-hefty-price-tag-drugs-com-mednews","status":"publish","type":"post","link":"https:\/\/platohealth.ai\/new-postpartum-depression-drug-zurzuvae-zuranolone-comes-with-hefty-price-tag-drugs-com-mednews\/","title":{"rendered":"New Postpartum Depression Drug, Zurzuvae (zuranolone), Comes With Hefty Price Tag – Drugs.com MedNews","gt_translate_keys":[{"key":"rendered","format":"text"}]},"content":{"rendered":"

Medically reviewed by Carmen Pope, BPharm<\/a>. Last updated on Nov 8, 2023.<\/span><\/p>\n

By Robin Foster HealthDay Reporter<\/p>\n

WEDNESDAY, Nov. 8, 2023 (Healthday News) — A new drug to treat postpartum depression<\/a> will cost nearly $16,000 for a 14-day course of treatment, a price tag that has doctors worried that some patients won’t be able to afford the medication.<\/p>\n

Zurzuvae<\/a> (zuranolone<\/a>) was first approved<\/a> by the U.S. Food and Drug Administration back in August, and it carried the distinction of being the first postpartum depression (PPD) drug that can be taken as a pill.<\/p>\n

Despite Zurzuvae’s high cost, drugmaker Sage Therapeutics said Tuesday that the drug should hit the market by December, and that it and partner Biogen are now talking with insurers about coverage of the medication.<\/p>\n

The companies\u2019 goal is \u201cto enable broad and equitable access for women with PPD who are prescribed this drug,\u201d Sage Chief Executive Officer Barry Greene<\/a> said in a company news release<\/a>. The hope is for patients to be able to get the medicine, \u201cwhere possible, with little to no co-pay regardless of financial means.\u201d He added that the two companies will also help cover costs or provide the drug-free to certain patients.<\/p>\n

Mental health experts have welcomed the drug’s approval, not just because it presents a new way to treat postpartum depression but also because it \u201cappears to be fast-acting,\u201d Dr. Catherine Monk<\/a>, chief of the Division of Women\u2019s Mental Health in the Department of Obstetrics and Gynecology at the Columbia University Vagelos College of Physicians and Surgeons in New York City, told CNN<\/em>.<\/p>\n

In one company trial, Zurzuvae improved<\/a> depressive symptoms in as little as three days.<\/p>\n

Prior to Zurzuvae’s approval, options to treat postpartum depression orally included selective serotonin reuptake inhibitors (SSRIs), but those antidepressants \u201ctake weeks to kick in and must continue being taken on a daily basis for at least six to 12 months,\u201d Dr. Katrina Furey<\/a>, a psychiatrist specializing in women\u2019s mental health and reproductive psychiatry and a clinical instructor at Yale University, told CNN<\/em>.<\/p>\n

Still, SSRIs typically cost much less: Prozac <\/a>and Zoloft<\/a>, and their generics, can run less than $20 a month, according to Drugs.com.<\/p>\n

\u201cIt remains to be seen how much insurance companies will cover it or if they will require women to \u2018fail\u2019 treatment with less expensive SSRIs before paying for this new treatment,\u201d Furey said. \u201cI hope that is not the case and that its price will not be a barrier to accessing this treatment.\u201d<\/p>\n

The $15,900 price \u201craises substantial accessibility concerns, especially when we still don\u2019t know how it\u2019ll be covered by insurance,\u201d Dr. Lindsay Allen<\/a>, an assistant professor of emergency medicine and a health economist and health services researcher at the Northwestern University Feinberg School of Medicine in Chicago, told CNN<\/em>.<\/p>\n

\u201cEnsuring access to such treatments is imperative, as they may be lifesaving for new mothers during a vulnerable time,\u201d Allen said. \u201cSuicide is a leading cause of death in the first year postpartum.\u201d<\/p>\n

Disclaimer:<\/strong> Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.<\/p>\n

<\/p>\n

\u00a9 2023 HealthDay. All rights reserved.<\/p>\n<\/div>\n

Posted November 2023<\/p>\n

\n

Read this next<\/h2>\n<\/p><\/div>\n

More news resources<\/h2>\n

Subscribe to our newsletter<\/h2>\n

Whatever your topic of interest, subscribe to our newsletters<\/a> to get the best of Drugs.com in your inbox.<\/p>\n